Post

Exeliom to focus on gastric cancer landscape with immune modulating drug

Paris-based Exeliom Biosciences will focus Phase III efforts of its immune modulating drug EXL01 in gastric cancer if it succeeds …

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy

US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead …

Hyundai Bioscience to conduct antiviral trials for Dengue in Brazil

Hyundai Bioscience has announced plans to conduct clinical trials in Brazil for its Niclosamide-based Dengue antiviral. The company’s decision comes after …

FDA approves Freedom Biosciences’s TRD treatment trial

The US Food and Drug Administration (FDA) has approved Freedom Biosciences’s investigational new drug (IND) application for FREE001, enabling the …

Caliway Biopharmaceuticals’ cellulite study meets endpoints

Taiwanese biopharmaceutical company Caliway Biopharmaceuticals has announced that a Phase II trial of its CBL-514 injection lipolysis therapy met all …